NCT02540759已完成1 期
Study of the Effect of Dose of Buglossoides Arvensis Oil on Eicosapentaenoic Acid Accrual and on the Inflammatory Response
Réseau de Santé Vitalité Health Network2 个研究点 分布在 1 个国家目标入组 88 人开始时间: 2015年9月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 88
- 试验地点
- 2
- 主要终点
- Plasma eicosapentaenoic concentration (EPA)
研究概览
简要总结
The effect of various doses of Buglossoides oil on the accrual of eicosapentaenoic acid (EPA) in blood and circulating cells will be investigated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men or non-pregnant women, using an effective form of birth control (such as oral contraceptives, injectable contraceptives or the barrier method such as a intrauterine device (IUD) with a spermicide, a diaphragm with a spermicide, a condom with a spermicide or a sponge with a spermicide) for at least 3 months prior to entry into the study and continuing during participation in the study.
- •18 to 65 years of age, inclusive.
- •Body mass index (BMI) 18 - 39.9 kg/m2
- •Subject is willing to avoid alcohol consumption for 24h prior to every clinic visit.
- •The subject will not modify smoking habits during supplementation period.
- •No significant medical conditions that in the opinion of the qualified physician, would preclude the subject's participation in the study.
- •Signed informed consent.
- •Willing to follow all study procedures including study visits, fasting blood draws, stable body weight, normal eating habits, current activity level, and compliance with study preparation.
- •Willing to not consume fish, crustaceans and shellfish for the duration of the study.
排除标准
- •Pregnancy or lactation. Women trying to conceive. Women who will try to conceive who are unwilling to commit to the use of a medically approved form of contraception throughout the study period. Method of contraception must be recorded in the case report file.
- •Individual has a condition the study physician believes would interfere with the participant's ability to provide informed consent, comply with his responsibilities during the study, which might confound the interpretation of the study results or put the person at undue risk.
- •Medical conditions including an active peptic ulcer, inflammatory bowel disease, or gastrointestinal bleeding and any medical condition or prior gastrointestinal surgery that could influence absorption, metabolism or excretion of the study supplement.
- •History or presence of significant, renal, hepatic, gastrointestinal, pulmonary, biliary, neurological or endocrine disorders.
- •History or presence of cancer in the past 2 yrs, except for non-melanoma skin cancers (e.g. basal or squamous cell carcinoma of the skin).
- •Clinically significant abnormal laboratory test results including but not limited to LDL-cholesterol ≥ 4.1mM, triglyceride levels ≥3.95mM, fasting creatinine ≥ 1.5 mg/dL, alanine transaminase or aspartate aminotransferase ≥ 1.5X the upper limit of normal.
- •Currently being treated for angina, arrhythmia and/or congestive heart failure. History of myocardial infarction or stroke.
- •Uncontrolled hypertension (resting systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg).
- •Type 1 or 2 diabetes. Fasting glucose ≥ 100 mg/dL. HbA1c ≥ 6.
- •If a smoker, subject smokes no more than 1 pack (20 cigarettes) daily.
- •History (within 12 months) or current alcohol or substance abuse (no more than 14 consumptions per week; 1 consumption= 12 oz beer, 5 oz wine, 1.5 oz distilled spirits).
- •Use of any lipid-altering medications (statins, bile acid sequestrants, cholesterol absorption inhibitors, fibrates, over the counter and prescription formulations of niacin).
- •Unstable use of thyroid medication. Stable, treated hypothyroidism is not an exclusion criteria.
- •Use of any weight loss or lipid metabolism medication/supplement/program (including lipase inhibitors) within 1 month of study period OR weight gain or loss > 2 kg in the past 3 months.
- •Currently taking fish oil or any other omega-3 or omega-6 polyunsaturated fatty acids (PUFA) supplement/drug within one month of Visit 1 and throughout the study. Consumption of fatty fish (salmon, herring, mackerel, albacore tuna, and sardines) more than 2X a month within one month of visit 1 and throughout the study period. Consumption (more than twice a month) of any EPA/DHA enriched foods (e.g. docosahexaenoic acid (DHA)-enriched eggs) within one month of Visit
- •Unwillingness to avoid all fish including shellfish and crustaceans throughout the study period.
- •Use of alpha-linolenic acid-containing seeds and oils such as flax seed, chia seed, perilla seed, hemp, spirulina, walnut, mustard seed or black currant seeds/oil within one month of Visit 1 and throughout the study.
- •Use of an investigational product within the previous 30 days.
- •Has donated blood up to 4 weeks before the start of the study. Not willing to cease being a blood donor during the study.
结局指标
主要结局
Plasma eicosapentaenoic concentration (EPA)
时间窗: Day 28
Expressed as μmol/L plasma
次要结局
- Plasma 20:4n-3(Day 28)
- Fasting serum chemistry: sodium(Day 28)
- Plasma docosapentaenoic acid (DPA)(Day 28)
- Mononuclear cell 20:4n-3, EPA and DPA individually as % of total fatty acids(Day 28)
- Plasma 20:4n-3, EPA and DPA individually as % of total fatty acids(Day 28)
- Fasting serum chemistry: glucose(Day 28)
- Fasting serum chemistry: potassium(Day 28)
- Fasting serum chemistry: blood urea nitrogen(Day 28)
- Fasting serum chemistry: aspartate aminotransferase(Day 28)
- Fasting hematology profile: monocytes (% WBC)(Day 28)
- Fasting hematology: hematocrit(Day 28)
- Fasting serum chemistry: calcium(Day 28)
- Fasting serum chemistry: amylase(Day 28)
- Fasting serum chemistry: albumin(Day 28)
- Urinalysis: appearance(Day 28)
- Fasting serum chemistry: alkaline phosphatase(Day 28)
- Fasting serum chemistry: creatinine(Day 28)
- Fasting serum chemistry: gamma-glutamyltransferase(Day 28)
- Fasting serum chemistry: total bilirubin(Day 28)
- Fasting serum chemistry: uric acid(Day 28)
- Fasting hematology: white blood cell count(Day 28)
- Fasting hematology: red blood cell count(Day 28)
- Fasting hematology: platelet count(Day 28)
- Fasting blood lipid profile: triglycerides(Day 28)
- Fasting hematology: neutrophil count(Day 28)
- Fasting hematology:hemoglobin(Day 28)
- Fasting blood lipid profile: total cholesterol(Day 28)
- Fasting blood lipid profile: low density lipoprotein cholesterol (LDL-c)(Day 28)
- Fasting blood lipid profile: non-high density lipoprotein-cholesterol (non-HDL-c)(Day 28)
- Fasting blood lipid profile: HDL-c(Day 28)
- Fasting serum chemistry: chloride(Day 28)
- Estimated glomerular filtration rate(Day 28)
- Fasting hematology profile: mean corpuscular volume(Day 28)
- Fasting hematology profile: mean corpuscular hemoglobin(Day 28)
- Fasting hematology profile: mean corpuscular hemoglobin concentration(Day 28)
- Fasting hematology profile: red cell distribution width(Day 28)
- Fasting hematology profile: mean platelet volume(Day 28)
- Fasting hematology profile: lymphocyte concentration(Day 28)
- Fasting hematology profile: monocyte count(Day 28)
- Fasting hematology profile: eosinophil count(Day 28)
- Fasting hematology profile: basophil count(Day 28)
- Fasting hematology profile: Immature granulocytes count(Day 28)
- Fasting hematology profile: immature granulocytes (% white blood cell (WBC))(Day 28)
- Fasting hematology profile: neutrophil (% WBC)(Day 28)
- Fasting hematology profile: lymphocyte (% WBC)(Day 28)
- Fasting hematology profile: eosinophil (% WBC)(Day 28)
- Fasting hematology profile: basophil (% WBC)(Day 28)
- Urinalysis: density(Day 28)
- Urinalysis: nitrites(Day 28)
- Urinalysis: pH(Day 28)
- Urinalysis: blood(Day 28)
- Urinalysis: leukocyte esterase(Day 28)
- Urinalysis: protein(Day 28)
- Urinalysis: glucose(Day 28)
- Urinalysis: acetone(Day 28)
- Urinalysis: urobilinogen(Day 28)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study of the Safety and Efficacy of Dietary Buglossoides OilHealthyNCT02226354Réseau de Santé Vitalité Health Network40
已完成
不适用
EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes MellitusDiabetes Mellitus Type IINCT03258840Tehran University of Medical Sciences36
招募中
不适用
A study on the effects of eicosapentaenoic acid (EPA) on arteriosclerosis in hemodialysis patients with percutaneous coronary intervention (PCI)Dialysis patients who have been subjected to PCI.JPRN-UMIN000002653agoya Kyoritsu Hospital100
Unknown
不适用
Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid StudyHeart DiseaseNCT01400490Cardiovascular Research Associates120
已完成
不适用
Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB PatientsMuscular Dystrophy, DuchenneNCT01826422Coordinación de Investigación en Salud, Mexico40